GlassScriptPhysician profile
Laura Danielle Smith
NPI 1205200227
$9,277.93
in general payments reported to CMS, 2019-2025
38 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,559 · 2022: $1,962 · 2023: $1,842 · 2024: $1,692 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,557 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,556.57 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,955.93 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,261.15 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $713.07 | 2021-2025 | Saphnelo, Evusheld |
| Novartis Pharmaceuticals Corporation | $709.07 | 2021-2025 | |
| Janssen Biotech, INC. | $590.30 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $546.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.78 | 2021-2025 | Ofev |
| Aurinia Pharma U.S., INC. | $362.58 | 2021-2025 | Lupkynis |
| Octapharma USA, INC. | $347.27 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Organon LLC | $277.43 | 2021-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $223.29 | 2021-2025 | Acthar |
| Radius Health, INC. | $205.17 | 2021-2024 | Tymlos |
| Glaxosmithkline, LLC. | $202.08 | 2023-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $200.15 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $163.05 | 2021-2023 | Taltz |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $142.07 | 2022-2024 | |
| Genentech USA, INC. | $133.92 | 2021-2025 | Actemra, Rituxan, Gazyva |
| E.R. Squibb & Sons, L.L.C. | $82.60 | 2023-2024 | Orencia |
| Fresenius Kabi USA, LLC | $74.87 | 2025 | Idacio |
| Hikma Pharmaceuticals USA | $69.21 | 2021-2022 | |
| Sobi, INC | $59.82 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $41.54 | 2023 | Belbuca |
| Alexion Pharmaceuticals, INC. | $41.09 | 2022-2023 | Strensiq |
| Tersera Therapeutics LLC | $39.62 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.36 | 2021-2022 | |
| Mentor Worldwide LLC | $39.06 | 2021 | |
| Sandoz INC. | $34.00 | 2024-2025 | Hyrimoz, Jubbonti |
| Pacira Pharmaceuticals Incorporated | $32.07 | 2023 | Iovera, Zilretta |
| Idorsia Pharmaceuticals US INC | $26.84 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $26.65 | 2021-2022 | |
| Mylan Institutional INC. | $25.88 | 2023 | Hulio |
| Kyowa Kirin, INC. | $20.72 | 2024 | Crysvita |
| Ibsa Pharma INC. | $20.52 | 2023 | Tirosint, Licart |
| Kiniksa Pharmaceuticals, LTD. | $19.38 | 2023 | Arcalyst |
| Antares Pharma, INC. | $16.79 | 2021 | |
| Depuy Synthes Sales INC. | $13.97 | 2021 | |
| Biocon Biologics INC | $13.60 | 2024 | Hulio |
| Avanos Medical | $13.33 | 2024 | Trivisc Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.